Home / Oncology (page 5)

Oncology

Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies

Ingelheim, Germany, 12 August 2019 – Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a new multi-year partnership to conduct collaborative research to rapidly advance therapies for various types of cancers, including gastrointestinal and lung cancers. The establishment of a joint Virtual Research and Development …

Read More »

Onconova Therapeutics and Mission Bio Partner to Advance Precision Oncology Clinical Trials Employing Single-Cell Genomics

NEWTOWN, Pa. and SOUTH SAN FRANCISCO, Calif., Aug. 12, 2019 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), and Mission Bio, the pioneer in targeted single-cell DNA analysis and precision genomics, …

Read More »

AstraZeneca’s Tagrisso Significantly Improved Overall Survival in the Phase 3 Trial for First-Line EGFR-Mutated NSCLC

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca today announced positive overall survival (OS) results from the Phase III FLAURA trial, a randomized, double-blinded, multicenter trial of TAGRISSO in previously-untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) mutations. TAGRISSO showed a statistically-significant and clinically-meaningful …

Read More »

Sasen Bio Reports Positive, Preliminary Data from Phase 3 Trial in High-Risk Non-Muscle Invasive Bladder Cancer

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 8, 2019– Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported updated, preliminary primary and secondary endpoint data from the Company’s Phase 3 VISTA trial further supporting the strong benefit-risk profile of Viciniumfor the potential treatment …

Read More »

Lynparza Meets Primary Endpoint in Phase 3 Trial in HRR Mutation-Selected Metastatic Castration-Resistant Prostate Cancer

WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase III PROfound trial of LYNPARZA 300 mg (two 150 mg tablets) twice daily in men with metastatic castration-resistant prostate cancer (mCRPC) who have a *homologous recombination repair …

Read More »

FDA Accepts Blueprint’s NDA for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST

CAMBRIDGE, Mass., Aug. 7, 2019 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for avapritinib for the treatment of …

Read More »

Jazz’s Investigational Crisantaspase Meets its Efficacy and Safety Objectives in its Phase 1 Study

DUBLIN, Aug. 6, 2019 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Phase 1 study of its recombinant crisantaspase molecule, JZP-458, met its efficacy and safety objectives. The company plans to initiate a single-arm, pivotal Phase 2/3 study evaluating JZP-458 as a potential treatment option for patients …

Read More »

Genentech’s Tecentriq Plus Chemotherapy Reduced the Risk of Disease Worsening or Death in Previously Untreated Advanced Bladder Cancer

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMvigor130 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS). The combination of Tecentriq® (atezolizumab) plus platinum-based chemotherapy showed a statistically significant reduction in the risk of disease …

Read More »

FDA Approves Daiichi Sankyo’s Turalio for the Treatment of TGCT, a Rare and Debilitating Tumor

Tokyo, Munich and Basking Ridge, NJ – (August 2, 2019) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration (FDA) approved TURALIO™ (pexidartinib) as the first and only treatment for adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to …

Read More »

Phase 3 Trial of Transgene’s Pexa-Vec Liver Cancer Halted Early Following Planned Interim Futility Analysis

Transgene (Paris:TNG), a biotech company designing and developing virus-based immunotherapies for the treatment of solid tumors, today announces that the independent Data Monitoring Committee (“IDMC”) of the PHOCUS study of Pexa-Vec in Liver Cancer has completed a planned interim futility analysis. Sillajen has informed Transgene of the IDMC’s recommendation to …

Read More »